Skip to main content

Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · Delayed Price · USD
27.36
-0.03 (-0.11%)
After-hours:Sep 17, 2021 7:58 PM EDT
27.39
-6.96 (-20.26%)
At close: Sep 17, 4:00 PM
Market Cap1.14B
Revenue (ttm)862,000
Net Income (ttm)n/a
Shares Out10.03M
EPS (ttm)-3.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,066,192
Open34.00
Previous Close34.35
Day's Range26.80 - 34.93
52-Week Range16.32 - 37.99
Betan/a
Analystsn/a
Price Target35.00 (+27.8%)
Est. Earnings DateOct 18, 2021

About JANX

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on our proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Our initial focus is on developing a novel class of T cell engagers (TCEs), an emerging class of immunotherapies that bridge a tumor cell and a T cell, to activate and redirect T cells to attack and eliminate tumors, and our lead product candidates are designed to target clinically validated drug targets. We are d...

IndustryBiotechnology
IPO DateJun 11, 2021
CEODavid Campbell, Ph.D.
Employees22
Stock ExchangeNASDAQ
Ticker SymbolJANX
Full Company Profile

Financial Performance

Financial Statements

News

Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...

1 week ago - Business Wire

Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...

1 week ago - Business Wire

Janux Therapeutics Reports Second Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today re...

1 month ago - Business Wire

Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Shahram Salek...

2 months ago - Business Wire

Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase...

LA JOLLA, Calif.--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previo...

3 months ago - Business Wire

Merck Partners With Newly Public Cancer Biotech

The 37th biotech to hit the public markets this year has a potentially $1 billion deal with Merck & Co. Inc. ( MRK , Financial).

Other symbols:MRK
3 months ago - GuruFocus

Janux Therapeutics Announces Pricing of Initial Public Offering

Janux Therapeutics, Inc. (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the pricing of its initial public offering of 11,400,000 shares of its comm...

3 months ago - Business Wire

Janux Therapeutics IPO Registration Document (S-1)

Janux Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC